Zach Fleming: Great indicator that we got 41 approvals before launch, so that was really encouraging to see that these hospitals as well as surgeons felt like there was a need and there was demand and so we were able to get the approval. And then since launched the American Association of the Knee Surgeons called AAHKS, as we call it, really great response. Just the booth was packed every day. There was a lot of questions about our scientists in the booth. We had our medical science team in the booth and a lot of interest in terms of just the ability for this product to have an impact on their surgeries. And that momentum has continued. We’ve seen a lot of uptake, a lot of surgeons. We’ve also seen a lot of distributors asking to add that product into their bag and their product mix. So we’re really excited about it.
Ian Cassel: And maybe when you think about — when investors think about BIASURGE, what is the kind of type of revenue for surgery on a product like that? I know accelerates several hundred dollars per surgery or somewhere around there. How should we think about BIASURGE? Is that $30 a surgery, 100 to 200, what range should we be thinking about?
Zach Fleming: Yes. We have just started pricing on that in those first facilities. And I’d tell you we’re averaging somewhere around $200 a unit right now. And that unit is one leader, and that would be — yet to be determined how many they use for surgery.
Ian Cassel: Okay. Excellent. And
Zach Fleming: That’s a pretty quick sample, but I just would share that with you here early.
Ian Cassel: And maybe switching to ALLOCYTE. How would you kind of characterize the demand you’re seeing now that you have supply again for that product? I mean is it — is the demand you’re seeing kind of back to the levels you saw before the supply disruption? And maybe just give us an indication of that.
Zach Fleming: Yes. The demand is there. It’s just a little bit of — little bit of a process to get back added to facilities. We did have to create the line extension ALLOCYTE Plus, and that needs to be added to the contract. So that’s really the biggest kind of stop gap of why we haven’t gotten back completely where we were, but we are selling — we are seeing a lot of pickup to that product. So we’re really okay with that.
Operator: Our next question is coming from Stephen Reed with Pitch Investments.
Unidentified Analyst: I think more to follow on Ian and Ross’ question. They had to most of them, but mine will be around Precision Healing on the imaging, what you’ve learned, if you learned anything from the FDA? And then what the process you see going forward on the lateral flow SA submission and approval?
Operator: It appears Mr. Nixon’s line has gone down for a moment, but he is dialing back in as we speak.
Zach Fleming: Well, if you want to repeat that real quick, Stephen, I was thinking Ron was going to feel that. But if you’d repeat that, I’ll answer.
Unidentified Analyst: Yes, sure. Really around the Precision Healing, what you’ve learned so far from your submission if you received any feedback and then going forward on the lateral flow assay or molecular assays, where you’re at with that, what you’ve learned and what the process would be for you to go forward with that technology?
Zach Fleming: We are working closely with the FDA on the multispectral imager. So we’ve gotten feedback on that and working for another submission and should have that feedback again shortly. So we’re working with them to resubmit LA, we have not announced, so I’m going to withhold comments on that particular component.
Unidentified Analyst: And have you received any feedback yet on going out looking for your appropriate partners for the Tissue health Plus — is the in a diagnosis that’s a critical piece of the process before you see that to materialize?
Ron Nixon: Yes. We’re — I’ll take that. This is Ron. The interest is high out there because everybody recognizes the potential opportunity of this — from our perspective, we believe that the market is much greater than what is reported in the market because it’s hard to capture the complete cost of loans because of all the comorbidities that they’ve got. But with most of the people that have the payer data, they understand that the complications from wounds related to diabetes, related to COPD, CHF, mobility with pressure ulcers, all types of things like that. When you look at the OEM costs, cost of amputation, cost of readmission back into the hospital, cost of these complications that may be associated with diabetes, but not labeled as the wound.
When you really look at all those and you think about our prevention program and then better solutions for treating these and avoidance of these, having people go to the wrong location to get their rooms taken care of, meaning higher call centers. All of that is going to be very appealing to the audience that we’re talking to. So at this time, we’re not prepared to talk about who those partners are, but there are numerous partners out there that would be interested in joining us with the effort that we put in over the last many years of building this platform.
Operator: Our next question is coming from Niraj Gupta with GCI Partners.
Niraj Gupta: A couple of questions, all related to BIASURGE. Could you guys just speak more broadly on BIASURGE? My understanding was that the product was applicable to virtually any surgery involving stealing the wound cavity, Zach, Ron. Could you guys just speak a little bit to just the broadness of the potential applicability for BIASURGE product?
Ron Nixon: Yes. I think let me clarify one thing. I’ll let Zach answer, but it’s to kill the bacteria in the room bed not to seal anything. It’s not a sealant but — I’ll exactly answer the question about the opportunity.
